Yes, Fasenra (benralizumab) is a biologic. Specifically, it is a humanized monoclonal antibody, a type of biologic drug made from living cells and engineered to target a precise part of the immune system. The FDA classifies Fasenra as an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, and it is used to treat severe eosinophilic asthma.
What Makes Fasenra a Biologic
Biologics are a class of drugs produced from living organisms rather than synthesized chemically like traditional pills. They tend to be large, complex protein molecules, and monoclonal antibodies like Fasenra are among the most common type. Because of their size and complexity, biologics are given by injection or infusion rather than taken orally.
Fasenra is delivered as a subcutaneous injection, meaning the needle goes just under the skin in the upper arm, thigh, or abdomen. The standard dose is 30 mg, given once every 4 weeks for the first three doses, then once every 8 weeks after that. That every-8-weeks maintenance schedule is one of the least frequent dosing intervals among asthma biologics.
How Fasenra Works
In severe eosinophilic asthma, a type of white blood cell called an eosinophil drives chronic airway inflammation. Eosinophils depend on a signaling molecule called interleukin-5 (IL-5) to grow, activate, and survive. Fasenra works by latching onto the IL-5 receptor on the surface of eosinophils, which does two things at once.
First, it physically blocks IL-5 from reaching the receptor, cutting off the growth signal. Second, and this is what sets Fasenra apart from some other biologics, it actively recruits natural killer cells to destroy the eosinophils directly. The natural killer cells release proteins that trigger the eosinophil to self-destruct, a process called apoptosis. This dual action leads to near-complete depletion of eosinophils in the blood and airways, rather than simply reducing their numbers.
How Quickly It Works
Fasenra can start improving asthma control faster than many patients expect. A real-world observational study found statistically significant improvements in asthma control scores within one week of the first injection. By week 2, improvements were both statistically significant and clinically meaningful for most measures. By week 8, more than half of patients (59.1%) had reached a level of improvement considered clinically relevant.
These early gains tend to hold. The same study tracked patients over 56 weeks and found sustained benefits throughout the treatment period.
Clinical Trial Results
Fasenra’s effectiveness was established in three major phase 3 trials. In the SIROCCO trial over 48 weeks, patients on Fasenra had 51% fewer asthma exacerbations than those on placebo. In the CALIMA trial over 56 weeks, the reduction was 28%. A third trial called ZONDA, which specifically looked at whether patients could reduce their oral steroid use, showed a 70% reduction in exacerbation rate compared to placebo.
The variation across trials reflects differences in patient populations and study design, but all three showed a consistent pattern: fewer flare-ups and better disease control for people with eosinophilic asthma.
How Fasenra Compares to Other Asthma Biologics
Fasenra is not the only biologic available for severe asthma, and the differences between them come down to what they target and how often you take them.
- Fasenra (benralizumab) targets the IL-5 receptor on eosinophils, destroying the cells directly. Dosed every 8 weeks after the loading phase.
- Nucala (mepolizumab) targets IL-5 itself, the signaling molecule, rather than its receptor. This reduces eosinophil levels but doesn’t directly kill the cells. Dosed monthly.
- Dupixent (dupilumab) blocks a different pair of signaling molecules (IL-4 and IL-13) and works for a broader range of asthma types, not just eosinophilic. Dosed every two weeks.
Some patients prefer Fasenra specifically because the every-8-weeks maintenance schedule means fewer injections over the course of a year. A Bayesian network meta-analysis noted this dosing convenience as a practical advantage, though the best biologic for any individual depends on their specific asthma profile and blood work.
Where Biologics Fit in Asthma Treatment
Biologics like Fasenra are not first-line treatments. Current asthma management guidelines reserve them for the most severe cases, typically after a patient has already tried high-dose inhaled corticosteroids and long-acting bronchodilators without adequate control. Biologics are introduced at the highest step of the treatment ladder, often alongside other add-on therapies like long-acting muscarinic antagonists.
The goal of adding a biologic is to reduce exacerbations, improve daily symptom control, and in many cases, lower or eliminate the need for oral corticosteroids, which carry significant long-term side effects like bone loss, weight gain, and increased infection risk.
What to Expect With Treatment
Fasenra is given as a single subcutaneous injection. The first three doses are spaced 4 weeks apart, then you transition to one injection every 8 weeks. The injection itself is quick, typically taking only a few seconds to administer. Monitoring after injection is recommended, as is standard practice with biologic agents, because allergic reactions are possible though uncommon.
The most commonly reported side effects include headache and sore throat. Injection site reactions, such as redness or mild pain at the injection site, can also occur but tend to be mild and short-lived. Serious allergic reactions including anaphylaxis have been reported rarely, which is why initial doses are typically given in a healthcare setting.